Literature DB >> 12937015

In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.

Ellie J C Goldstein1, Diane M Citron, C Vreni Merriam, Yumi A Warren, Kerin L Tyrrell, Helen T Fernandez.   

Abstract

ABT-492 exhibited excellent in vitro activities against all 326 aerobic and anaerobic antral puncture sinus isolates tested with MICs (in micrograms per milliliter) at which 90% of the isolates tested were inhibited as follows: Haemophilus influenzae, 0.001; Moraxella catarrhalis, 0.008; and Streptococcus pneumoniae, 0.015. It was four- to sixfold more active than other fluoroquinolones, including against levofloxacin-resistant strains of S. pneumoniae, methicillin-resistant Staphylococcus aureus, and Prevotella species.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12937015      PMCID： PMC182602          DOI： 10.1128/AAC.47.9.3008-3011.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults.

Authors:  S M Finegold; M J Flynn; F V Rose; H Jousimies-Somer; C Jakielaszek; M McTeague; H M Wexler; E Berkowitz; B Wynne
Journal:  Clin Infect Dis       Date:  2002-07-24       Impact factor: 9.079

2.  Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.

Authors:  H Tomioka; K Sato; H Kajitani; T Akaki; S Shishido
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Widespread use of fluoroquinolones versus emerging resistance in pneumococci.

Authors:  Ellie J C Goldstein; Susan M Garabedian-Ruffalo
Journal:  Clin Infect Dis       Date:  2002-12-04       Impact factor: 9.079

4.  Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.

Authors:  C Urban; N Rahman; X Zhao; N Mariano; S Segal-Maurer; K Drlica; J J Rahal
Journal:  J Infect Dis       Date:  2001-08-09       Impact factor: 5.226

Review 5.  Anaerobic bacteria in upper respiratory tract and other head and neck infections.

Authors:  Itzhak Brook
Journal:  Ann Otol Rhinol Laryngol       Date:  2002-05       Impact factor: 1.547

6.  Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.

Authors:  P L Ho; R W Yung; D N Tsang; T L Que; M Ho; W H Seto; T K Ng; W C Yam; W W Ng
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

7.  Emergence of penicillin-nonsusceptible Streptococcus pneumoniae invasive clones in Canada.

Authors:  D Greenberg; D P Speert; E Mahenthiralingam; D A Henry; M E Campbell; D W Scheifele
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

8.  Comparative in vitro activities of amoxicillin-clavulanate against aerobic and anaerobic bacteria isolated from antral puncture specimens from patients with sinusitis.

Authors:  E J Goldstein; D M Citron; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

9.  Bacteriological findings of acute maxillary sinusitis in young adults.

Authors:  H R Jousimies-Somer; S Savolainen; J S Ylikoski
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

10.  Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study.

Authors:  C Thornsberry; P T Ogilvie; H P Holley; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191
View more
  5 in total

1.  In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Robert K Flamm; Paul R Rhomberg; Michael D Huband; David J Farrell
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

3.  In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections.

Authors:  S McCurdy; L Lawrence; M Quintas; L Woosley; R Flamm; C Tseng; S Cammarata
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014.

Authors:  M A Pfaller; H S Sader; P R Rhomberg; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 5.  Delafloxacin: design, development and potential place in therapy.

Authors:  Francisco Javier Candel; Marina Peñuelas
Journal:  Drug Des Devel Ther       Date:  2017-03-20       Impact factor: 4.162
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.